Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Common Equity: 2022-2024

Historic Common Equity for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to $33.0 million.

  • Orchestra BioMed Holdings' Common Equity fell 5.37% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.7 million, marking a year-over-year decrease of 5.37%. This contributed to the annual value of $33.0 million for FY2024, which is 51.56% down from last year.
  • According to the latest figures from FY2024, Orchestra BioMed Holdings' Common Equity is $33.0 million, which was down 51.56% from $68.0 million recorded in FY2023.
  • Orchestra BioMed Holdings' 5-year Common Equity high stood at $68.0 million for FY2023, and its period low was $33.0 million during FY2024.
  • Its 3-year average for Common Equity is $51.2 million, with a median of $52.5 million in 2022.
  • In the last 5 years, Orchestra BioMed Holdings' Common Equity increased by 29.52% in 2023 and then plummeted by 51.56% in 2024.
  • Yearly analysis of 3 years shows Orchestra BioMed Holdings' Common Equity stood at $52.5 million in 2022, then rose by 29.52% to $68.0 million in 2023, then plummeted by 51.56% to $33.0 million in 2024.